Keros Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $223.5M | $228.6M |
| Jun 2022 | — | $211.2M | $215.6M |
| Sep 2022 | — | $241.0M | $239.4M |
| Dec 2022 | — | $277.4M | $279.0M |
| Mar 2023 | — | $355.0M | $351.4M |
| Jun 2023 | — | $326.3M | $322.0M |
| Sep 2023 | — | $295.8M | $287.9M |
| Dec 2023 | — | $332.2M | $331.1M |
| Mar 2024 | — | $453.9M | $442.4M |
| Jun 2024 | — | $420.9M | $405.9M |
| Sep 2024 | — | $532.8M | $530.7M |
| Dec 2024 | — | $571.6M | $559.9M |
| Mar 2025 | — | $728.9M | $720.5M |
| Jun 2025 | — | $706.7M | $690.2M |
| Sep 2025 | — | $703.6M | $693.5M |
| Dec 2025 | — | $303.1M | $287.4M |
| Mar 2026 | — | $285.6M | $281.5M |
| Jun 2026 | — | $262.3M | $257.6M |